ArticleCancer epidemiology2026
The association between body fatness and prevalent MGUS in the U.S. general population.
Article in Cancer epidemiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveCurrent evidence regarding the association between obesity and monoclonal gammopathy of undetermined significance (MGUS) remains inconsistent. This study aims to evaluate the relationship between objectively measured obesity markers and prevalent MGUS using nationally representative data from the U.S. POPULATION:
methodData came from the third National Health and Nutrition Examination Survey III (1988-1994) and continuous NHANES (1999-2004). We estimated multivariable-adjusted odds ratios (aORs) and 95 % confidence intervals (CIs) for the association between MGUS and seven obesity markers (i.e., baseline body mass index (BMI), maximum lifetime BMI, waist circumference (WC), waist-hip ratio (WHR), total body fat, fat-free mass, and body fat percentage) using logistic regression. Body composition was assessed using dual-energy X-ray absorptiometry (DXA) in NHANES 1999-2004 and tetrapolar bioelectrical impedance analysis (BIA) in NHANES III.
resultsThe study included 200 participants with MGUS in NHANES III (1988-1994) and 164 with MGUS in NHANES 1999-2004, compared with 12,043 participants without MGUS. In multivariate logistic regression analysis with DXA measurements, each 1 %age point increase in body fat percentage was associated with a 4 % higher odds of MGUS (aOR: 1.04, 95 % CI [1.01, 1.07]) and a 6 % higher odds of non-IgM MGUS (aOR: 1.06, 95 % CI [1.02, 1.10]). No statistically significant associations were found between MGUS and other obesity markers, including baseline BMI, maximum lifetime BMI, WC, WHR, and fat-free mass.
conclusionOur findings indicate that obesity is associated with an increased odds of MGUS. However, many obesity markers, including the commonly used BMI, do not adequately capture this association.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.